Randomised trials are challenging to conduct, and even when well designed, post-randomisation events will occur during follow-up, which affect the interpretation of results. For instance, patients may stop taking their allocated treatment and/or withdraw from the study, they may receive rescue medication, or they may die before the outcome can be measured. These issues can pose a challenge to the interpretation of the trial and are often the source of debate around the validity of results. In November 2019, ICH issued an addendum to ICH E9 (R1) entitled Estimands and Sensitivity Analyses in Clinical Trials to address such issues.
The purpose of this webinar will be to explain ICH E9 (R1) and how it impacts clinical development plans.
Alan Phillips, PhD, BSc, CStat, Senior Director Biostatistics, ICON Clinical Research
Dr. Alan Phillips is Senior Director Biostatistics providing consultancy services to the Pharmaceutical Industry. Prior to this role, he was Vice President Head of Biostatistics for ICON Clinical Research where he directed and managed the global biostatistics resources based in US, Europe and Asia Pac. With over 35 years of experience in biostatistics, Dr. Phillips has extensive knowledge of clinical trials, statistical methodology and worldwide statistical regulatory requirements. Prior to joining ICON, Dr. Phillips was with Wyeth Research for over 12 years and served as Senior Director, Clinical Biostatistics. Subsequently Dr. Phillips has both CRO and Pharma experience.
Dr. Phillips has experience in regulatory submissions in Biosimilars (Rituximab, Herception), CNS (depression, insomnia, Generalized Anxiety Disorder), Cardiovascular (Hypertension), Oncology (Breast Cancer) and Women’s Health (Hormone Replacement Therapy, Oral Contraceptives). For example, Dr. Phillips was recently involved in developing and justifying the sample size and statistical strategy for managing missing data for a biosimilar development program with the FDA. Dr. Phillips has also represented sponsors at US and EU scientific advisory and approval meetings.
Dr. Phillips received his BSc degree in mathematics from the University of Exeter and his PhD in statistics from the University of Birmingham. He has published in a number of areas including adaptive trial designs, estimands and sensitivity analyses, patient recruitment modelling, regulatory statistical challenges (e.g. missing data, multiplicity), sample size estimation and statistical principals for clinical trials. Dr. Phillips is affiliated with the Royal Statistical Society (RSS) and Statisticians in the Pharmaceutical Industry (PSI). In 2012, Dr. Phillips was made an Honorary member of PSI in recognition of his scientific contributions to the organisation. Dr. Phillips is also an Adjunct Associate Professor at University College Dublin and visiting Senior Lecturer at King’s College.Message Presenter
Tim Clark, Dip. Stat., PhD, Vice-President, Clinical Sciences, ICON Clinical Research GmbH
Dr. Tim Clark gained his PhD in clinical trial methodology at the Institute for Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilians-University, Munich. Dr. Clark is part of the Drug Development Services group, which provides strategic drug development advice to customers and internal teams. Dr. Clark specialises in clinical study design and protocol optimisation.
Prior to joining ICON in 2009, Dr. Clark worked in clinical research and regulatory affairs for large French and American pharmaceutical companies and as an independent consultant advising on a range of drug development issues. He has worked on small molecule and biological (including biosimilars) programmes indicated for cancer as well as CNS, autoimmune, cardiovascular and infectious diseases.
Dr. Clark has published on clinical study design, protocol optimisation and sample size determination in peer-reviewed journals and is currently an Honorary Associate Professor at the Institute of Clinical Trials & Methodology, University College London.Message Presenter
Who Should Attend?
Executives, directors, scientists and managers from pharma and biotech responsible for the clinical development of drug products, including those in:
- Research and development
- Clinical operations
- Clinical science
- Biostatistics and Programming
- Medical Writing
- Outcomes research
- Outsourcing and procurement
- Regulatory Affairs
ICON plc is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently operates from 98 locations in 40 countries and has approximately 15,100 employees. Further information is available at ICONplc.com.